All Products are stable to be shipped at room temperature, unless otherwise specified.
| Pack Size | Quantity | Price (USD) | Sub Total |
|---|---|---|---|
| 10mg | $ 127.00 | 0.0 | |
| 50mg | $ 305.00 | 0.0 | |
| 100mg | $ 523.00 | 0.0 | |
| Exact Weight Packaging | $ 145.00 | 0.0 | |
| Total | $ 0.0 | ||
Product successfully added to cart.
- Request another packsize ? Click here.
- Inventory Status : Pending QC
- Ships On : 6/16/2023
G601510
Bulk Order Request for G601510
Product Description
| Catalogue Number | G601510 |
| Chemical Name | GDC-0941 |
| Synonyms | 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine; 4-[2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine; GDC 0941; GDC 941; GNE 0941; Pictilisib; Pictrelisib |
| CAS Number | 957054-30-7 |
| Molecular Formula | C₂₃H₂₇N₇O₃S₂ |
| Appearance | White to Off-White Solid |
| Melting Point | >200ºC (dec.) |
| Molecular Weight | 513.64 |
| Storage | -20°C |
| Solubility | DMSO (Slightly), Methanol (Slightly, Heated) |
| Category | Research Tools; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| Applications | GDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC-0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models. Potent PI3K inhibitor. |
| References | Jeffrey J.W., et al.: Clinical. Cancer. Rsch., 10, 1078 (2012); Murray, J.M., et al.: J. Medn. Chem., 55, 7686 (2012); |